KEY OPINION LEADERS
This treatment would be of high value since at this time we don’t have any neuroprotective agents available.
Prof. Dr. Heinz Reichmann, PhD, FRCP. Professor and Chair Dept. Neurology, Dresden
Former president of the German Neurology and Parkinson associations
These are incredible results and, if confirmed in patients, will change the way we treat neurology patients.
Prof. Dr. Wolfgang H. Oertel. Hertie Professor and former Chair Dept. Neurology, Marburg.
Former president of the German Neurology and Parkinson associations
The targeted disease indications have a high medical need and promise high revenues in case of success. The concept of moving fast into human is convincing.
Dr. Matthias Urmann. President of the “Gesellschaft Deutscher Chemiker” 2018-2019 and Head of External Innovation at Sanofi
PATIENTS
In summary, the two active substances have had a positive, i.e. slowing, effect on the course of the disease. Compared to existing treatments, I don´t know of any other one with such a promising effect.
In my opinion, these substances should be further developed to enter the clinical phase.
Markus Ihm, ALS patient